PTGS2 and ovarian cancer: Cyclooxygenase-2 (COX-2) expression causes several changes in the tumor microenvironment (TME) of ovarian cancer, which are associated with a low immunotherapy response in patients and immunosuppression in the TME, mainly due to cytotoxic T-lymphocyte-associated-protein-4 (CTLA-4) expression.